{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-24-000018","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.280189+00:00","generated_at":"2026-06-05T03:53:03.239501+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gossamer Bio Q4/FY23 results: first PAH patient dosed in Phase 3 PROSERA, cash $296M into H1 2026","bullets":["First PAH patient dosed in registrational Phase 3 PROSERA study; topline results expected Q4 2025.","Japan PMDA accepted CTN, allowing inclusion of Japanese sites without PK bridging; could support Japanese NDA.","Cash, equivalents & marketable securities $296.4M at Dec 31, 2023; expected to fund operations into H1 2026.","Net loss for FY2023: $179.8M ($1.18 per share) vs $229.4M ($2.71) in FY2022.","R&D expenses FY2023: $135.3M vs $170.9M in FY2022; G&A: $38.5M vs $47.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-24-000018","json":"https://secwatch.observer/filing/0001728117-24-000018.json","markdown":"https://secwatch.observer/filing/0001728117-24-000018.md","text":"https://secwatch.observer/filing/0001728117-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000018/0001728117-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000018/goss-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:53:03.239501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18064fbd845eeeeb4215d802b6007e33feab9ad2","claim":"Gossamer Bio, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 5, 2024 , Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000018/0001728117-24-000018-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}